Omarigliptin
Omarigliptin[edit | edit source]
Omarigliptin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones in the body. These hormones help to regulate blood glucose levels by increasing insulin release and decreasing glucagon levels.
Mechanism of Action[edit | edit source]
Omarigliptin functions by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the degradation of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By inhibiting DPP-4, omarigliptin prolongs the action of these hormones, thereby enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner.
Pharmacokinetics[edit | edit source]
Omarigliptin is administered orally and is known for its once-weekly dosing schedule, which is a result of its long half-life. This makes it a convenient option for patients who may have difficulty adhering to daily medication regimens. The drug is absorbed in the gastrointestinal tract and is metabolized primarily in the liver.
Clinical Use[edit | edit source]
Omarigliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin to achieve better glycemic control. It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Side Effects[edit | edit source]
Common side effects of omarigliptin include nasopharyngitis, headache, and upper respiratory tract infection. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis and hypersensitivity reactions. Patients should be monitored for signs and symptoms of these conditions.
Contraindications[edit | edit source]
Omarigliptin is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with a history of pancreatitis.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
